{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT05132777","nct_id":"NCT05132777","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05132777. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"JMT101 in combination with Osimertinib","type":"EXPERIMENTAL"}],"collaborators":["CSPC ZhongQi Pharmaceutical Technology Co., Ltd."],"completion_date":{"date":"2024-09-30","type":"ESTIMATED"},"conditions":["Locally Advanced or Metastatic Non-Small Cell Lung Cancer","EGFR Exon20 Insertion Mutations"],"enrollment":{"count":155,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"JMT101","otherNames":[],"type":"DRUG"},{"name":"Osimertinib Mesylate Tablets","otherNames":[],"type":"DRUG"}],"last_update":"2021-11-24","lead_sponsor":"Shanghai JMT-Bio Inc.","official_title":"A Phase II, Open Label, Multi-center Study to Assess the Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2023-09-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Confirmed Objective Response Rate (ORR) Assessed by Blinded Independent Review Committee (IRC) per RECIST Version 1.1","timeFrame":"From the first dose to disease progression or end of study, an average of 1 year"}],"references":[],"start_date":{"date":"2021-11-20","type":"ESTIMATED"},"study_type":"INTERVENTIONAL","title":"Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT05132777"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05132777"}